Epigenetics Pharma, LLC, based in Mercer Island, WA, is a pioneering pharmaceutical company focused on developing innovative treatments for cancer. Their groundbreaking drug, iMN041, combines a DNA methyl transferase inhibitor (DNMTI) and a ribonucleotide reductase inhibitor (RNRI) to upregulate tumor suppressor genes and stimulate a potent antitumor immune response. With a unique approach that addresses the shortcomings of current drugs, Epigenetics Pharma aims to harness the patient's own immune system to effectively treat solid tumors such as triple negative breast cancer and pancreatic cancer. Through their drug iMN013 and its prodrug iMN041, Epigenetics Pharma has demonstrated significant advancements in immunotherapy. iMN041 has shown remarkable efficacy in upregulating both the innate and adaptive immune system, while decreasing the possibility of tumor immune escape. By increasing the ratio of CD8-T cells to Treg cells and CD4-T cells to Treg cells, iMN041 enhances the antitumor immune response and has shown promising results in mouse models of human cancer, including the most challenging solid tumors. With their commitment to delivering on the promise of epigenetics, Epigenetics Pharma is revolutionizing cancer treatment through their innovative immunotherapeutic approach.Generated from the website